Nephroblastoma-Overexpressed Protein as a Prognostic Marker for High Disease Activity in Iraqi Patients with Rheumatoid Arthritis
DOI:
https://doi.org/10.54133/ajms.v6i2.910Keywords:
Anti-MCV, Disease activity, CCN3, IL-6, Rheumatoid arthritis, Rheumatoid factorAbstract
Background: Many data indicate a strong relationship between CCN3 and the intensity and length of RA symptoms. Furthermore, RA patients' bone deterioration, joint degeneration, and impaired functional status strongly correlate with serum CCN3 levels. Objective: To evaluate the levels of CCN3 protein, IL6, and anti-MCV biomarkers with the activity of RA disease and determine if there is any relationship between CCN3, anti-MCV, and IL6 in RA patients. Methods: In this prospective case-control study, 60 patients with RA were selected and subdivided according to disease activity, and 60 healthy individuals were served as controls. An enzyme-linked immunosorbent test (ELISA) was used to evaluate blood levels of CCN3, RF, anti-CCP, anti-MCV, and IL-6. Results: A significant correlation was reported for CCN3 with high and moderate disease activity and ulnar deformity but not with IL6, anti-MCV, anti-CCP, sex, or duration of disease. There is a strong positive correlation between anti-MCV and disease duration, as well as anti-MCV and RF. Conclusions: CCN3 has a significant association with disease activity and joint deformity with high sensitivity and specificity compared to other parameters, making it a good prognostic biomarker for RA.
Downloads
References
Radu AF, Bungau SG. Nanomedical approaches in the realm of rheumatoid arthritis. Ageing Res Rev. 2023:101927. doi: 10.1016/j.arr.2023.101927. DOI: https://doi.org/10.1016/j.arr.2023.101927
Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591-602. doi: 10.1038/s41584-022-00827-y. DOI: https://doi.org/10.1038/s41584-022-00827-y
Kojima M, Kawahito Y, Sugihara T, Kojima T, Harada R, Hirata S, et al. Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design. BMC Rheumatol. 2022;6(1):1-8. doi: 10.1186/s41927-022-00322-7. DOI: https://doi.org/10.1186/s41927-022-00322-7
Croia C, Bursi R, Sutera D, Petrelli F, Alunno A, Puxeddu I. One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):347-357. PMID: 31111823.
Dekkers JS, Verheul MK, Stoop JN, Liu B, Ioan-Facsinay A, van Veelen PA, et al. Breach of autoreactive B cell tolerance by post-translationally modified proteins. Ann Rheum Dis. 2017;76(8):1449-1457. doi: 10.1136/annrheumdis-2016-210772. DOI: https://doi.org/10.1136/annrheumdis-2016-210772
Barra L, Bykerk V, Pope JE, Haraoui BP, Hitchon CA, Thorne JC, et al. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. J Rheumatol. 2013;40(8):1259-1267. doi: 10.3899/jrheum.120736. DOI: https://doi.org/10.3899/jrheum.120736
Volkov M, van Schie KA, van der Woude D. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunol Rev. 2020;294(1):148-163. doi: 10.1111/imr.12829. DOI: https://doi.org/10.1111/imr.12829
Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. 2010;12(1):1-8. doi: 10.1186/ar2903. DOI: https://doi.org/10.1186/ar2903
Nigm DA, Abdel-Lateef HH, Hashim J, Kamal D. Antibodies against a mutated citrullinated vimentin in patients with rheumatoid arthritis. Egypt J Immunol. 2022;29(4):184-194. doi: 10.55133/eji.290418. DOI: https://doi.org/10.55133/eji.290418
Henrot P, Truchetet ME, Fisher G, Taïeb A, Cario M. CCN proteins as potential actionable targets in scleroderma. Exp Dermatol. 2019;28(1):11-18. doi: 10.1111/exd.13806. DOI: https://doi.org/10.1111/exd.13806
Wei Y, Peng L, Li Y, Zhang N, Shang K, Duan L, et al. Higher serum CCN3 is associated with disease activity and inflammatory markers in rheumatoid arthritis. J Immunol Res. 2020;2020. doi: 10.1155/2020/3891425. DOI: https://doi.org/10.1155/2020/3891425
Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020;217(5). doi: 10.1084/jem.20190347. DOI: https://doi.org/10.1084/jem.20190347
Malysheva K, Rooij KD, WGM Löwik C, Baeten D, Rose-John S. Interleukin 6/Wnt interactions in rheumatoid arthritis: interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts. Croatian Med J. 2016;57(2):89-98. doi: 10.3325/cmj.2016.57.89. DOI: https://doi.org/10.3325/cmj.2016.57.89
Al-Rawi Z, Alazzawi A, Alajili F, Alwakil R. Rheumatoid arthritis in population samples in Iraq. Ann Rheum Dis. 1978;37(1):73-75. doi: 10.1136/ard.37.1.73. DOI: https://doi.org/10.1136/ard.37.1.73
Al-Ubaidi AH, Al-Ani MM, Al-Bidri KZ. Comparism between Anti-RA33, Anti-CCP antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Iraqi patients. J Fac Med Baghdad. 2013;55(1):64-67. doi: 10.32007/jfacmedbagdad.551672.
Al-Karkhi MA, Al-Ani MM, Jassim NA. Development of anti-bodies against infliximab in Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad. 2015;57(3):241-243. doi: 10.32007/med.1936/jfacmedbagdad.v57i3.14. DOI: https://doi.org/10.32007/jfacmedbagdad.573372
Mohammed AM, Zayni SM, AL-Anee MM, Corial FI, Al-Rubaee A. Diagnostic and predictive values of IL-6 in a group of Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad. 2023;65(2). doi: 10.32007/jfacmedbagdad.2044. DOI: https://doi.org/10.32007/jfacmedbagdad.2044
Abdul-Wahid K, Al-Derzi A, Al-Osami M, Al-Ani M. Serum levels of adiponectin before and after administration of anti-tumor necrosis factor agents in Iraqi patients with rheumatoid arthritis. Int J Immunol Res. 2013;3(2):50.
Zayed NS, Obaid RF, Hamza AA. Association of cellular communication network factor 3 (CCN3) with rheumatoid arthritis disease and its severity (Case-control study). Med Sci J Adv Res. 2022;3(4):201-208. doi: 10.46966/msjar.v3i4.85. DOI: https://doi.org/10.46966/msjar.v3i4.85
Lee Y, Bae S, Song G. Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis. Zeitschrift fur Rheumatologie. 2015;74(10):911-918. doi: 10.1007/s00393-015-1598-x. DOI: https://doi.org/10.1007/s00393-015-1598-x
Sghiri R, Bouajina E, Bargaoui D, Harzallah L, Fredj HB, Sammoud S, et al. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int. 2008;29:59-62. doi: 10.1007/s00296-008-0614-8. DOI: https://doi.org/10.1007/s00296-008-0614-8
El Shazly RI, Hussein SA, Raslan HZ, Elgogary AA. Anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis patients: Relation to disease activity and manifestations. Egypt Rheumatologist. 2014;36(2):65-70. doi: 10.1016/j.ejr.2013.12.009. DOI: https://doi.org/10.1016/j.ejr.2013.12.009
Nass FR, Skare TL, Goeldner I, Nisihara R, Messias-Reason IT, Utiyama SR. Analysis of four serum biomarkers in rheumatoid arthritis: association with extra articular manifestations in patients and arthralgia in relatives. Revista Brasileira de Reumatologia. 2017;57:286-293. doi: 10.1016/j.rbr.2015.11.002. DOI: https://doi.org/10.1016/j.rbre.2016.03.001
Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008;58(1):36-45. doi; 10.1002/art.23188. DOI: https://doi.org/10.1002/art.23188
Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Alkaabi J. Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Omani patients with rheumatoid arthritis. Int J Rheumatol. 2012;2012. doi: 10.1155/2012/285854. DOI: https://doi.org/10.1155/2012/285854
Reyes-Castillo Z, Palafox-Sánchez C, Parra-Rojas I, Martínez-Bonilla G, del Toro-Arreola S, Ramírez-Dueñas M, et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol. 2015;182(2):119-131. doi: 10.1111/cei.12677. DOI: https://doi.org/10.1111/cei.12677
Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti–cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Int Med. 2007;146(11):797-808. doi: 10.7326/0003-4819-146-11-200706050-00008. DOI: https://doi.org/10.7326/0003-4819-146-11-200706050-00008
Nell V, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005;64(12):1731-1736. doi: 10.1136/ard.2005.035691. DOI: https://doi.org/10.1136/ard.2005.035691
Ateş A, Kinikli G, Turgay M, Akay G, Tokgöz G. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol. 2007;26:538-545. doi: 10.1007/s10067-006-0343-x. DOI: https://doi.org/10.1007/s10067-006-0343-x
Abdullah HN, Al-Thuwani AN, Nadir MI, Al-Badri K. Diagnostic value of Anti-CCP antibodies compared with Rheumatoid factor in Rheumatoid arthritis patients. J Anbar Univ Pure Sci. 2012;7(1). doi: 10.37652/juaps.2012.78249. DOI: https://doi.org/10.37652/juaps.2012.78249
Al-Ubaidi AH. Comparison between anti-RA33, anti-CCP antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Iraqi patients. J Fac Med Baghdad. 2013;55(1):68-71. doi: 10.32007/jfacmedbagdad.551672. DOI: https://doi.org/10.32007/jfacmedbagdad.551672
Porto LSS, Tavares WC, Costa DAdS, Lanna CCD, Kakehasi AM. Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a magnetic resonance imaging study. Revista brasileira de reumatologia. 2017;57:15-22. doi: 10.1016/j.rbr.2015.07.009. DOI: https://doi.org/10.1016/j.rbre.2015.07.018
Yoshii I, Sawada N, Chijiwa T. Associations between clinical metrics of joint deformity, disease duration, disease activity, functional capacity, quality of life, pain, and fatigue in patients with rheumatoid arthritis. Clin Rheumatol. 2023;42(4):1027-1038. doi: 10.1007/s10067-022-06432-4. DOI: https://doi.org/10.1007/s10067-022-06432-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).